# Supplementary table

|  |
| --- |
| ***Supplementary table 1:*** Demographics of all OASIS patients, deselected patients and the study population.  |
|  | All OASIS patients (n=217) | Deselected patients (n=95) | Study population (122) | p-value |
| Age (years) | 45.4 (13.0) | 45.7 (13.9) | 45.2 (12.3) | 0.80 |
| Symptom duration (years) | 22.4 (12.4) | 21.0 (12.8) | 23.5 (12.1) | 0.16 |
| Disease duration (years) | 13.2 (9.6) | 12.2 (9.3) | 14.1 (10.0) | 0.15 |
| ASDAS | 2.7 (1.1) | 2.8 (1.1) | 2.6 (1.0) | 0.13 |
| BASDAI (0-10) | 3.4 (2.1) | 3.5 (2.0) | 3.4 (2.3) | 0.83 |
| CRP (mg/L) | 16.4 (24.2) | 20.0 (28.3) | 13.7 (20.2) | 0.059 |
| Elevated CRP, n (%) | 98 (46.5) | 46 (47.3) | 55 (45.8) | 0.84  |
| ESR (mm/h) | 15.5 (15.8) | 16.9 (17.1) | 14.4 (14.6) | 0.25 |
| PGDA (0-10) | 3.9 (2.8) | 4.0 (2.9) | 3.8 (2.6) | 0.50 |
| Spinal pain (0-10) | 3.6 (2.4) | 3.7 (2.6) | 3.5 (2.3) | 0.45 |
| mSASSS (0-72) | 14.2 (18.4) | 15.0 (19.8) | 13.9 (17.6) | 0.77 |
| Sex, male, n (%) | 154 (71.3) | 68 (72.3) | 86 (70.5) | 0.77  |
| HLAB27 positive, n (%) | 174 (84.5) | 77 (88.5) | 97 (81.5) | 0.17  |
| mSASSS>0, n (%) | 158 (85.4) | 52 (82.5) | 106 (86.9) | 0.43  |
| NSAID intake, n (%) | 160 (74.1) | 65 (69.2) | 95 (77.9) | 0.15  |
| TNFi intake, n (%) | 11 (5.1) | 0 (0) | 11 (9.0) | 0.003  |

ASDAS-CRP: Ankylosing Spondylitis disease activity score - C-Reactive protein. BASDAI: Bath Ankylosing Spondylitis disease activity index. ESR: Erythrocyte sedimentation rate. C1M, C5M and C6M: MMP-mediated degradation of type I, V and VI collagen, respectively. VICM: Citrullinated and MMP-degraded vimentin. mSASSS: modified Stoke Ankylosing Spondylitis Spine. NSAIDs: non-steroidal anti-inflammatory drugs; TNFi intake: tumor necrosis factor inhibitor intake.